It is great to note that ReNeuron’s hRPC cell therapy candidate for the treatment of retinitis pigmentosa is progressing into the Phase II element of the ongoing Phase I/II clinical trial. It proved to be safe and well tolerated at the three doses tested in the Phase I portion of the trial. Data from the Phase II trial is expected in H2 2018 with efficacy data from the Phase IIb element in 2020. ReNeuron continues to make positive developments with its ophthalmology and stroke programmes and we ....
08 Nov 2017
N+1 Singer - ReNeuron Group - Clinical trial in retinitis pigmentosa progressing into Phase II
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - ReNeuron Group - Clinical trial in retinitis pigmentosa progressing into Phase II
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
08 Nov 2017 -
Author:
Sheena Berry -
Pages:
3
It is great to note that ReNeuron’s hRPC cell therapy candidate for the treatment of retinitis pigmentosa is progressing into the Phase II element of the ongoing Phase I/II clinical trial. It proved to be safe and well tolerated at the three doses tested in the Phase I portion of the trial. Data from the Phase II trial is expected in H2 2018 with efficacy data from the Phase IIb element in 2020. ReNeuron continues to make positive developments with its ophthalmology and stroke programmes and we ....